CClinicalTrials.gg
RecruitingNCT07622953VIOLETUpdated Jun 3, 2026

Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers

An observational study in Gynaecological Cancers, sponsored by University Hospital Southampton NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by University Hospital Southampton NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
Female
01

Study summary

This study will investigate vaginal secretions in those patients with cancer versus those who are cancer free and compare changes in specific markers that change when a cancer first develops.

Patients who are being investigated for any gynaecological cancer, undergoing surgery to reduce their risk of gynaecological cancer and those with confirmed gynaecological cancer undergoing anti-cancer treatment will be approached to take part in this study.

Participants will be asked to provide an extra blood test, urine sample and high vaginal swab in addition to surplus primary tissue and ascitic fluid that is left over from routine surgical procedures. Specific markers will be compared in patients who have evidence of gynaecological cancer versus those that do not. Changes in these markers during anti-cancer treatment will also be compared to see how these change over time. This could improve the detection and monitoring of gynaecological cancers in those people at highest risk of developing it by using non-invasive multi-cancer early detection tests developed at the University of Southampton.

02

Conditions studied

  • Gynaecological Cancers

Keywords

  • Gynaecological cancers
  • Biomarker
  • Multi-Cancer Early Detection
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be identified by clinically- and research-trained investigators from routine clinical service and their clinical data from electronic NHS databases.

Inclusion criteria

  • Suspected cohort: Individuals undergoing investigations for suspected gynaecological cancer. This includes patients undergoing surgery to reduce their risk of the development of gynaecological cancers in the future
  • Confirmed treatment cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing anti-cancer treatment including surgical resection, chemotherapy or radiotherapy as part of their routine clinical care
  • Confirmed palliative cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing palliative procedures including ascitic drainage as part of their routine clinical care

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years old
  • Individuals who lack capacity to consent to trial participation
  • Pregnant or breastfeeding patients
  • Patients with active vaginal infection
  • Patients currently on or having received antibiotics within the previous week
  • History of prior malignancy or chronic inflammatory disease
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Suspected for Gynaecological Cancers

    Individuals undergoing investigations for suspected gynaecological cancer. Includes those undergoing surgery to reduce their risk of the development of gynaecological cancers in the future.

  • Confirmed Gynaecological Cancer

    Individuals with a confirmed gynaecological cancer diagnosis undergoing anti-cancer treatment including surgical resection, chemotherapy or radiotherapy as part of their routine clinical care.

  • Confirmed Palliative Gynaecological Cancer

    Individuals with a confirmed gynaecological cancer diagnosis undergoing palliative procedures including ascitic drainage as part of their routine clinical care.

05

What researchers measure

Primary outcomes

  1. Development of a non-invasive diagnostic and prognostic tool for the detection and monitoring of gynaecological cancers using biomarkers in vaginal fluid.

    Sequential exploratory analysis of vaginal fluid will be undertaken, such as microbiome, genomic, epigenomic, metabolomic, transcriptomic and phenotypic analysis. This data will be compared with multiomics analysis of paired tissue plus plasma/blood/urine/ascitic fluid then correlated with clinical outcome.

    Time frame: From enrolment to 5 years post last participant enrolled

06

Study locations

1 of 1 sites recruiting
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07622953
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
Experimental Cancer Medicine Centres, The Eve Appeal, Southampton Clinical Trials Unit, Daye BioTech, University of Oxford
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jan 14, 2026
Primary completion
Mar 2, 2030 (estimated)
Completion
Jul 2, 2030 (estimated)
Last update
Jun 3, 2026

Study contacts

Dr Jemma Longley
Contact
violetstudy@uhs.nhs.uk
023 8120 5154
Dr Jemma Longley
principal investigator · University Hospital Southampton NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion